Pacira BioSciences' Cash from Operations rose 12.82% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.4 million, marking a year-over-year decrease of 30.61%. This contributed to the annual value of $189.4 million for FY2024, which is 22.46% up from last year.
Pacira BioSciences' Cash from Operations amounted to $60.8 million in Q3 2025, which was up 406.44% from $12.0 million recorded in Q2 2025.
Pacira BioSciences' Cash from Operations' 5-year high stood at $60.8 million during Q3 2025, with a 5-year trough of $12.0 million in Q2 2025.
Its 3-year average for Cash from Operations is $41.1 million, with a median of $44.4 million in 2023.
Per our database at Business Quant, Pacira BioSciences' Cash from Operations spiked by 292.87% in 2021 and then crashed by 77.44% in 2025.
Over the past 5 years, Pacira BioSciences' Cash from Operations (Quarterly) stood at $23.2 million in 2021, then spiked by 81.08% to $42.0 million in 2022, then rose by 13.20% to $47.6 million in 2023, then slumped by 30.37% to $33.1 million in 2024, then rose by 12.82% to $60.8 million in 2025.
Its last three reported values are $60.8 million in Q3 2025, $12.0 million for Q2 2025, and $35.5 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value